OMB APPROVAL

 

 

OMB Number:

3235-0578

 

 

Expires:

March 31, 2019

 

UNITED STATES

Estimated average burden hours per response . . . . . . . . . . 10.5

 

SECURITIES AND EXCHANGE COMMISSION

 

 

Washington, D.C. 20549

 

 

FORM N-Q

 

QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED
MANAGEMENT INVESTMENT COMPANY

 

Investment Company Act file number

811-06565

 

Tekla Life Sciences Investors

(Exact name of registrant as specified in charter)

 

100 Federal Street, 19th Floor, Boston, MA

 

02110

(Address of principal executive offices)

 

(Zip code)

 

 

(Name and address of agent for service)

 

Registrant’s telephone number, including area code:

617-772-8500

 

 

Date of fiscal year end:

September 30

 

 

Date of reporting period:

6/30/18

 

 



 

Item 1.  Schedule of Investments.

 



 

TEKLA LIFE SCIENCES INVESTORS

SCHEDULE OF INVESTMENTS

JUNE 30, 2018

(Unaudited)

 

SHARES

 

 

 

VALUE

 

 

 

 

 

 

 

 

 

CONVERTIBLE PREFERRED AND WARRANTS (a) - 4.4% of Net Assets

 

 

 

 

 

 

 

 

 

 

 

Biotechnology — 1.0%

 

 

 

1,400,000

 

Amphivena Therapeutics, Inc. Series B (Restricted) (b)

 

$

2,100,000

 

1,153,847

 

BioClin Therapeutics, Inc. Series A (Restricted) (b)

 

750,001

 

668,449

 

BioClin Therapeutics, Inc. Series B (Restricted) (b)

 

500,000

 

933,333

 

GenomeDx Biosciences, Inc. Series C (Restricted) (b) 

 

310,800

 

160,424

 

GenomeDx Biosciences, Inc. Series D Prime (Restricted) (b)

 

146,788

 

816,948

 

GenomeDx Biosciences, Inc. Series D (Restricted) (b)

 

249,169

 

112,645

 

GenomeDx Biosciences, Inc. Warrants (Restricted, expiration 11/1/27, exercise price $0.31) (b)

 

0

 

90,000

 

Trillium Therapeutics, Inc. Series II (d)

 

540,000

 

 

 

 

 

4,596,758

 

 

 

Health Care Equipment & Supplies (Restricted) — 2.4%

 

 

 

2,338,198

 

AlterG, Inc. Series C (b)

 

233,820

 

79,330

 

CardioKinetix, Inc. Series C, 8.00% (b)

 

0

 

142,574

 

CardioKinetix, Inc. Series D, 8.00% (b)

 

0

 

439,333

 

CardioKinetix, Inc. Series E, 8.00% (b)

 

0

 

481,378

 

CardioKinetix, Inc. Series F, 8.00% (b)

 

0

 

N/A

(g)

CardioKinetix, Inc. Warrants (expiration 12/11/19, exercise price $0.69) (b)

 

0

 

N/A

(g)

CardioKinetix, Inc. Warrants (expiration 6/03/20, exercise price $0.69) (b)

 

0

 

8,822

 

CardioKinetix, Inc. Warrants (expiration 8/15/24, exercise price $2.85) (b)

 

0

 

951,000

 

IlluminOss Medical, Inc. Series AA, 8.00% (b) (c)

 

951,000

 

895,848

 

IlluminOss Medical, Inc. Junior Preferred, 8.00% (b) (c)

 

895,848

 

47,542

 

IlluminOss Medical, Inc. Warrants (expiration 1/11/28, exercise price $1.00) (b) (c)

 

0

 

23,771

 

IlluminOss Medical, Inc. Warrants (expiration 11/20/27, exercise price $1.00) (b) (c)

 

0

 

47,542

 

IlluminOss Medical, Inc. Warrants (expiration 2/06/28, exercise price $1.00) (b) (c)

 

0

 

71,324

 

IlluminOss Medical, Inc. Warrants (expiration 3/31/27, exercise price $1.00) (b) (c)

 

0

 

2,606,033

 

Veniti, Inc. Series A, 8.00% (b) (c)

 

4,541,534

 

1,307,169

 

Veniti, Inc. Series B, 8.00% (b) (c)

 

2,343,362

 

716,720

 

Veniti, Inc. Series C, 8.00% (b) (c)

 

1,448,849

 

 

 

 

 

10,414,413

 

 

 

Life Sciences Tools & Services (Restricted) — 0.8%

 

 

 

2,446,016

 

Labcyte, Inc. Series C, 8.00% (b)

 

3,081,980

 

107,178

 

Labcyte, Inc. Series D, 8.00% (b)

 

147,906

 

81,480

 

Labcyte, Inc. Series E, 8.00% (b)

 

131,183

 

 

 

 

 

3,361,069

 

 



 

SHARES

 

 

 

VALUE

 

 

 

 

 

 

 

 

 

Pharmaceuticals (Restricted) — 0.2%

 

 

 

659,244

 

Milestone Pharmaceuticals, Inc. Series C (b)

 

$

900,000

 

 

 

 

 

 

 

 

 

 

TOTAL CONVERTIBLE PREFERRED AND WARRANTS
(Cost $21,148,839)

 

19,272,240

 

 

 

 

 

 

 

PRINCIPAL
AMOUNT

 

 

 

 

 

 

 

 

 

 

 

 

 

CONVERTIBLE NOTES (Restricted) — 0.3% of Net Assets

 

 

 

 

 

 

 

 

 

 

 

Biotechnology — 0.1%

 

 

 

$

349,198

 

Amphivena Therapeutics, Inc. Promissory Note, 6.00% due 6/20/19 (b)

 

349,198

 

 

 

 

 

 

 

 

 

Health Care Equipment & Supplies — 0.2%

 

 

 

12,336

 

AlterG, Inc. Promissory Note, 6.00% due 9/8/18

 

12,336

 

51,741

 

CardioKinetix, Inc. Promissory Note, 5.00% due 7/31/18 (a) (b) 

 

0

 

285,294

 

IlluminOss Medical, Inc. Promissory Note, 8.00% due 12/31/18 (b) (c) 

 

285,294

 

95,083

 

IlluminOss Medical, Inc. Promissory Note, 8.00% due 12/31/18 (b) (c) 

 

95,083

 

190,166

 

IlluminOss Medical, Inc. Promissory Note, 8.00% due 12/31/18 (b) (c) 

 

190,166

 

190,166

 

IlluminOss Medical, Inc. Promissory Note, 8.00% due 12/31/18 (b) (c) 

 

190,166

 

 

 

 

 

773,045

 

 

 

TOTAL CONVERTIBLE NOTES
(Cost $1,174,630)

 

1,122,243

 

 

 

 

 

 

 

SHARES

 

 

 

 

 

 

 

 

 

 

 

 

 

COMMON STOCKS AND WARRANTS - 88.0% of Net Assets

 

 

 

 

 

 

 

 

 

 

 

Biotechnology — 69.9%

 

 

 

4,120

 

AbbVie Inc.

 

381,718

 

52,739

 

AC Immune SA (a) (d)

 

490,473

 

37,607

 

ACADIA Pharmaceuticals Inc. (a)

 

574,259

 

616,000

 

Achillion Pharmaceuticals, Inc. (a)

 

1,743,280

 

362,631

 

Adaptimmune Therapeutics plc (a) (e)

 

4,304,430

 

360,000

 

Affimed N.V. (a)

 

594,000

 

82,582

 

Akebia Therapeutics, Inc. (a)

 

824,168

 

38,333

 

Albireo Pharma, Inc. (a)

 

1,360,821

 

116,178

 

Alexion Pharmaceuticals, Inc. (a)

 

14,423,499

 

47,341

 

Alkermes plc (a)

 

1,948,556

 

42,503

 

Alnylam Pharmaceuticals, Inc. (a)

 

4,186,120

 

145,998

 

Amarin Corporation plc (a) (e)

 

451,134

 

157,553

 

Amgen Inc.

 

29,082,708

 

270,622

 

Amicus Therapeutics, Inc. (a)

 

4,227,116

 

 



 

 

SHARES

 

 

 

VALUE

 

 

 

 

 

 

 

 

 

Biotechnology — continued

 

 

 

811,227

 

ARCA biopharma, Inc. (a) (c)

 

$

451,042

 

324,491

 

ARCA biopharma, Inc. Warrants (expiration 6/11/22, exercise price $6.10) (a) (b) (c)

 

74,633

 

320,135

 

Ardelyx, Inc. (a)

 

1,184,500

 

31,474

 

Arena Pharmaceuticals, Inc. (a)

 

1,372,266

 

38,931

 

argenx SE (a) (e)

 

3,225,823

 

70,136

 

Array Biopharma Inc. (a)

 

1,176,882

 

17,877

 

Ascendis Pharma A/S (a) (e)

 

1,189,178

 

10,078

 

BeiGene, Ltd. (a) (e)

 

1,549,291

 

60,000

 

Bellicum Pharmaceuticals, Inc. (a)

 

442,800

 

108,039

 

Biogen Inc. (a)

 

31,357,239

 

52,024

 

BioMarin Pharmaceutical Inc. (a)

 

4,900,661

 

23,412

 

bluebird bio, Inc. (a)

 

3,674,513

 

32,267

 

Blueprint Medicines Corporation (a)

 

2,048,309

 

297,980

 

Celgene Corporation (a)

 

23,665,572

 

74,700

 

Cellectis S.A. (a) (e)

 

2,113,263

 

158,784

 

Cidara Therapeutics, Inc. (a)

 

825,677

 

22,800

 

Clovis Oncology, Inc. (a)

 

1,036,716

 

54,956

 

CRISPR Therapeutics AG (a)

 

3,229,215

 

78,899

 

Dermira, Inc. (a)

 

725,871

 

42,419

 

Editas Medicine, Inc. (a)

 

1,519,873

 

329

 

Eiger BioPharmaceuticals, Inc. Warrants (expiration 10/10/18, exercise price $84.15) (a) (b)

 

0

 

164,575

 

Epizyme, Inc. (a)

 

2,229,991

 

28,785

 

Esperion Therapeutics, Inc. (a)

 

1,128,084

 

155,074

 

Exelixis, Inc. (a)

 

3,337,192

 

66,438

 

FibroGen, Inc. (a)

 

4,159,019

 

24,824

 

Galapagos NV (a) (d)

 

2,288,429

 

10,180

 

Galapagos NV (a) (e)

 

938,392

 

447,128

 

Gilead Sciences, Inc.

 

31,674,548

 

22,687

 

Global Blood Therapeutics, Inc. (a)

 

1,025,452

 

178,214

 

Incyte Corporation (a)

 

11,940,338

 

47,712

 

Innoviva, Inc. (a)

 

658,426

 

51,530

 

Intellia Therapeutics, Inc. (a)

 

1,409,861

 

29,451

 

Ionis Pharmaceuticals, Inc. (a)

 

1,227,223

 

33,395

 

Iovance Biotherapeutics, Inc. (a)

 

427,456

 

10,127

 

Jounce Therapeutics, Inc. (a)

 

77,573

 

4,965

 

Loxo Oncology, Inc. (a)

 

861,328

 

122,504

 

Merus N.V. (a) (d)

 

2,788,191

 

62,194

 

Molecular Templates, Inc. (a)

 

325,275

 

73,792

 

Nektar Therapeutics (a)

 

3,603,263

 

79,711

 

Neurocrine Biosciences, Inc. (a)

 

7,830,809

 

63,211

 

NewLink Genetics Corporation (a)

 

300,884

 

358,000

 

Novavax, Inc. (a)

 

479,720

 

9,823

 

NuCana plc (a) (e)

 

186,637

 

160,747

 

Ovid Therapeutics Inc. (a)

 

1,253,827

 

563,608

 

Pieris Pharmaceuticals, Inc. (a)

 

2,857,493

 

 



 

SHARES

 

 

 

VALUE

 

 

 

 

 

 

 

 

 

Biotechnology — continued

 

 

 

23,821

 

Pieris Pharmaceuticals, Inc., Series A Warrants (expiration 6/8/21, exercise price $3.00) (a) (b)

 

$

50,739

 

11,911

 

Pieris Pharmaceuticals, Inc., Series B Warrants (expiration 6/8/21, exercise price $2.00) (a) (b)

 

31,445

 

37,141

 

Portola Pharmaceuticals, Inc. (a)

 

1,402,816

 

74,951

 

Protagonist Therapeutics, Inc. (a)

 

503,671

 

23,629

 

Puma Biotechnology, Inc. (a)

 

1,397,655

 

66,647

 

Ra Pharmaceuticals, Inc. (a)

 

663,138

 

45,395

 

Regeneron Pharmaceuticals, Inc. (a)

 

15,660,821

 

36,695

 

Sage Therapeutics, Inc. (a)

 

5,743,868

 

28,532

 

Sangamo Therapeutics, Inc. (a)

 

405,154

 

66,039

 

Sarepta Therapeutics, Inc. (a)

 

8,729,035

 

67,110

 

Seattle Genetics, Inc. (a)

 

4,455,433

 

22,046

 

Spark Therapeutics, Inc. (a)

 

1,824,527

 

200,000

 

Syndax Pharmaceuticals, Inc. (a)

 

1,404,000

 

35,266

 

TESARO, Inc. (a)

 

1,568,279

 

135,000

 

Trillium Therapeutics Inc. (a) (d)

 

810,000

 

23,539

 

Ultragenyx Pharmaceutical Inc. (a)

 

1,809,443

 

37,741

 

uniQure N.V. (a)

 

1,426,610

 

7,142

 

United Therapeutics Corporation (a)

 

808,117

 

141,093

 

Vertex Pharmaceuticals Incorporated (a)

 

23,980,166

 

70,484

 

Xenon Pharmaceuticals Inc. (a)

 

648,453

 

 

 

 

 

306,688,387

 

 

 

Health Care Equipment & Supplies — 2.6%

 

 

 

49,500

 

Alliqua BioMedical, Inc. (a)

 

101,475

 

130,000

 

Cercacor Laboratories, Inc. (Restricted) (a) (b)

 

387,360

 

49,264

 

IDEXX Laboratories, Inc. (a)

 

10,736,596

 

7,157

 

TherOx, Inc. (Restricted) (a) (b)

 

143

 

 

 

 

 

11,225,574

 

 

 

Health Care Providers & Services (Restricted) — 0.1%

 

 

 

148,148

 

InnovaCare Health, Inc. (a) (b) (f)

 

391,111

 

 

 

 

 

 

 

 

 

Life Sciences Tools & Services — 5.6%

 

 

 

75,374

 

Illumina, Inc. (a)

 

21,051,204

 

74,250

 

NanoString Technologies, Inc. (a)

 

1,015,740

 

13,090

 

Thermo Fisher Scientific Inc.

 

2,711,463

 

 

 

 

 

24,778,407

 

 

 

Pharmaceuticals — 9.8%

 

 

 

58,428

 

Acceleron Pharma Inc. (a)

 

2,834,927

 

236,260

 

Aerpio Pharmaceuticals, Inc. (a)

 

980,479

 

2,810

 

Agios Pharmaceuticals, Inc. (a)

 

236,686

 

317,800

 

Avadel Pharmaceuticals plc (a) (e)

 

1,948,114

 

82,665

 

Clearside Biomedical, Inc. (a)

 

883,689

 

169,962

 

CymaBay Therapeutics, Inc. (a)

 

2,280,890

 

62,973

 

Depomed, Inc. (a)

 

420,030

 

78,966

 

Endo International plc (a)

 

744,649

 

 



 

SHARES

 

 

 

VALUE

 

 

 

 

 

 

 

 

 

Pharmaceuticals — continued

 

 

 

124,140

 

Foamix Pharmaceuticals Ltd. (a) (d)

 

$

621,941

 

20,875

 

GW Pharmaceuticals plc (a) (e)

 

2,912,897

 

38,683

 

Jazz Pharmaceuticals plc (a)

 

6,665,081

 

35,194

 

Medicines Company (The) (a)

 

1,291,620

 

293,914

 

Mylan N.V. (a)

 

10,622,052

 

43,329

 

Revance Therapeutics, Inc. (a)

 

1,189,381

 

13,967

 

Shire plc (e)

 

2,357,630

 

366,534

 

Teligent, Inc. (a)

 

1,268,208

 

284,378

 

Tetraphase Pharmaceuticals, Inc. (a)

 

1,015,229

 

88,034

 

TherapeuticsMD, Inc. (a)

 

549,332

 

8,083

 

Theravance Biopharma, Inc. (a)

 

183,322

 

929,053

 

Verona Pharma plc (a) (d)

 

1,734,957

 

115,500

 

Verona Pharma plc (a) (e) 

 

1,588,125

 

371,622

 

Verona Pharma plc Warrants (expiration 4/27/22, exercise price $2.07) (a) (b) (d)

 

176,610

 

10,914

 

Zogenix, Inc. (a)

 

482,399

 

 

 

 

 

42,988,248

 

 

 

TOTAL COMMON STOCKS AND WARRANTS
(Cost $273,414,967)

 

386,071,727

 

 

 

 

 

 

 

 

 

EXCHANGE TRADED FUND - 2.6% of Net Assets

 

 

 

121,460

 

SPDR S&P Biotech ETF

 

11,561,777

 

 

 

TOTAL EXCHANGE TRADED FUND
(Cost $8,564,136)

 

11,561,777

 

 

PRINCIPAL
AMOUNT

 

 

 

 

 

 

 

SHORT-TERM INVESTMENT - 3.5% of Net Assets

 

 

 

$

15,474,000

 

Repurchase Agreement, Fixed Income Clearing Corp., repurchase value $15,474,000, 0.35%, dated 06/29/18, due 07/02/18 (collateralized by U.S. Treasury Note 2.25%, due 11/15/25, market value $15,785,630)

 

15,474,000

 

 

 

TOTAL SHORT-TERM INVESTMENT
(Cost $15,474,000)

 

15,474,000

 

 

 

TOTAL INVESTMENTS BEFORE MILESTONE INTERESTS - 98.8%
(Cost $319,776,572)

 

433,501,987

 

 

INTEREST

 

 

 

 

 

 

 

 

 

 

 

 

 

MILESTONE INTERESTS (Restricted)(a) (b) - 1.2% of Net Assets

 

 

 

 

 

 

 

 

 

 

 

Pharmaceuticals — 1.2%

 

 

 

1

 

Afferent Milestone Interest

 

331,794

 

1

 

Ethismos Research, Inc. Milestone Interest

 

0

 

1

 

Neurovance Milestone Interest

 

1,883,922

 

1

 

TargeGen Milestone Interest

 

3,111,853

 

 

 

TOTAL MILESTONE INTERESTS
(Cost $3,782,227)

 

5,327,569

 

 

 

TOTAL INVESTMENTS - 100.0%
(Cost $323,558,799)

 

$

438,829,556

 

 

 

OTHER LIABILITIES IN EXCESS OF ASSETS - 0.0%

 

(98,920

)

 

 

NET ASSETS - 100%

 

$

438,730,636

 

 



 


(a)         Non-income producing security.

(b)         Security fair valued using significant unobservable inputs. See Investment Valuation and Fair Value Measurements.

(c)          Affiliated issuers in which the Fund holds 5% or more of the voting securities (total market value of $11,466,977).

(d)         Foreign security.

(e)          American Depository Receipt

(f)           Security exempt from registration under Rule 144A of the Securities Act of 1933, as amended.  These securities may be resold in transactions exempt from registration, normally to qualified institutional buyers.

(g)   Number of warrants to be determined at a future date

 



 

TEKLA LIFE SCIENCES INVESTORS

NOTES TO SCHEDULE OF INVESTMENTS

June 30, 2018

(Unaudited)

 

Investment Valuation

 

Shares of publicly traded companies listed on national securities exchanges or trading in the over-the-counter market are typically valued at the last sale price, as of the close of trading, generally 4 p.m., Eastern time. The Board of Trustees of the Fund (the “Trustees”) has established and approved fair valuation policies and procedures with respect to securities for which quoted prices may not be available or which do not reflect fair value. Convertible bonds, corporate and government bonds are valued using a third-party pricing service. Convertible bonds are valued using this pricing service only on days when there is no sale reported. Restricted securities of companies that are publicly traded are typically valued based on the closing market quote on the valuation date adjusted for the impact of the restriction as determined in good faith by Tekla Capital Management LLC (the Adviser) also using fair valuation policies and procedures approved by the Trustees described below. Non-exchange traded warrants of publicly traded companies are generally valued using the Black-Scholes model, which incorporates both observable and unobservable inputs. Short-term investments with a maturity of 60 days or less are generally valued at amortized cost, which approximates fair value.

 

Convertible preferred shares, warrants or convertible note interests in private companies, milestone interests, and other restricted securities, as well as shares of publicly traded companies for which market quotations are not readily available, such as stocks for which trading has been halted or for which there are no current day sales, or which do not reflect fair value, are typically valued in good faith, based upon the recommendations made by the Adviser pursuant to fair valuation policies and procedures approved by the Trustees.

 

The Adviser has a Valuation Sub-Committee comprised of senior management which reports to the Valuation Committee of the Board at least quarterly. Each fair value determination is based on a consideration of relevant factors, including both observable and unobservable inputs. Observable and unobservable inputs the Adviser considers may include (i) the existence of any contractual restrictions on the disposition of securities; (ii) information obtained from the company, which may include an analysis of the company’s financial statements, the company’s products or intended markets or the company’s technologies; (iii) the price of the same or similar security negotiated at arm’s length in an issuer’s completed subsequent round of financing; (iv) the price and extent of public trading in similar securities of the issuer or of comparable companies; or (v) a probability and time value adjusted analysis of contractual terms. Where available and appropriate, multiple valuation methodologies are applied to confirm fair value. Significant unobservable inputs identified by the Adviser are often used in the fair value determination. A significant change in any of these inputs may result in a significant change in the fair value measurement. Due to the uncertainty inherent in the valuation process, such estimates of fair value may differ significantly from the values that would have been used had a ready market for the investments existed, and differences could be material. Additionally, changes in the market environment and other events that may occur over the life of the investments may cause the gains or losses ultimately realized on these investments to be different from the valuations used at the date of this Schedule of Investments.

 

Federal Income Tax Cost

 

At June 30, 2018, the cost of securities for Federal income tax purposes was $323,559,980. The net unrealized gain on securities held by the Fund was $115,269,576, including gross unrealized gain of $165,402,915 and gross unrealized loss of $50,133,339.

 

Other Transactions with Affiliates

 

An affiliate company is a company in which the Fund holds 5% or more of the voting securities. Transactions involving such companies during the period ended June 30, 2018 were as follows:

 



 

TEKLA LIFE SCIENCES INVESTORS

NOTES TO SCHEDULE OF INVESTMENTS

June 30, 2018

(Unaudited, continued)

 

Affiliated
Companies

 

Beginning
Value as of
September
30, 2017

 

Purchases at
Cost

 

Proceeds
from Sales

 

Net Realized
Gain/(Loss)
on sale of
Affiliated
Companies

 

Change in
Unrealized
Appreciation/
Depreciation

 

Ending Value
as of
June 30, 2018

 

Shares/
Principal
Amount
as of
June 30,
2018

 

Dividend
Income
from
Affiliated
Companies

 

Capital Gain
Distributions
from Affiliated
Companies

 

ARCA Biopharma, Inc.

 

$

924,799

 

 

 

 

 

 

$

(399,124

)

$

525,675

 

1,135,718

 

 

 

 

EBI Life Sciences, Inc.

 

13,102

 

 

 

 

$

(13,597

)

495

 

*

 

 

 

 

Euthymics Biosciences, Inc.

 

 

 

 

 

(2,673,162

)

2,673,162

 

*

 

 

 

 

IlluminOss Medical, Inc.

 

142,647

**

$

485,766

 

 

 

1,979,144

 

2,607,557

 

2,797,736

 

$

58,055

 

 

Veniti, Inc.

 

2,917,509

 

266

 

 

 

5,415,970

 

8,333,745

 

4,629,922

 

 

 

 

 

$

3,998,057

 

$

486,032

 

$

 

$

(2,686,759

)

$

9,669,647

 

$

11,466,977

 

8,563,376

 

$

58,055

 

$

 

 


* Not an affiliate at June 30, 2018.

** Not an affiliate at September 30, 2017.

 

Fair Value Measurements

 

The Fund uses a three-tier hierarchy to prioritize the assumptions, referred to as inputs, used in valuation techniques to measure fair value. The three-tier hierarchy of inputs is summarized in the three broad levels. Level 1 includes quoted prices in active markets for identical investments. Level 2 includes prices determined using other significant observable inputs (including quoted prices for similar investments, interest rates, credit risk, etc.). The independent pricing vendor may value bank loans and debt securities at an evaluated bid price by employing methodologies that utilize actual market transactions, broker-supplied valuations, and/or other methodologies designed to identify the market value for such securities and such securities are considered Level 2 in the fair value hierarchy. Level 3 includes prices determined using significant unobservable inputs (including the Fund’s own assumptions in determining the fair value of investments). These inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

 

For the nine month period ended June 30, 2018, there was a transfer between Level 2 and 1 and no other transfers between Levels. The amount of transfers between Level 2 and Level 1 was $2,432,360. The investment was transferred from Level 2 to Level 1 due to a removal of a trading restriction and the value is being supported by quoted prices. The Fund accounts for transfers between Levels at the beginning of the period.

 

The following is a summary of the levels used as of June 30, 2018 to value the Fund’s net assets.

 

Assets at Value

 

Level 1

 

Level 2

 

Level 3

 

Total

 

Convertible Preferred And Warrants

 

 

 

 

 

 

 

 

 

Biotechnology

 

$

540,000

 

 

 

$

4,056,758

 

$

4,596,758

 

Health Care Equipment & Supplies

 

 

 

 

10,414,413

 

10,414,413

 

Life Sciences Tools & Services

 

 

 

 

3,361,069

 

3,361,069

 

Pharmaceuticals

 

 

 

 

900,000

 

900,000

 

Convertible Notes

 

 

 

 

 

 

 

 

 

Biotechnology

 

 

 

 

349,198

 

349,198

 

Health Care Equipment & Supplies

 

 

 

 

773,045

 

773,045

 

Common Stocks And Warrants

 

 

 

 

 

 

 

 

 

Biotechnology

 

306,531,570

 

 

 

156,817

 

306,688,387

 

Health Care Equipment & Supplies

 

10,838,071

 

 

 

387,503

 

11,225,574

 

Health Care Providers & Services

 

 

 

 

391,111

 

391,111

 

Life Sciences Tools & Services

 

24,778,407

 

 

 

 

24,778,407

 

Pharmaceuticals

 

42,811,638

 

 

 

176,610

 

42,988,248

 

Exchange Traded Fund

 

11,561,777

 

 

 

 

11,561,777

 

Short-term Investment

 

 

$

15,474,000

 

 

15,474,000

 

Milestone Interest

 

 

 

 

 

 

 

 

 

Pharmaceuticals

 

 

 

5,327,569

 

5,327,569

 

Other Assets

 

 

 

262,059

 

262,059

 

Total

 

397,061,463

 

15,474,000

 

26,556,152

 

439,091,615

 

 



 

TEKLA LIFE SCIENCES INVESTORS

NOTES TO SCHEDULE OF INVESTMENTS

June 30, 2018

(Unaudited, continued)

 

The following is a reconciliation of Level 3 assets for which significant unobservable inputs were used to determine fair value.

 

Investments in Securities

 

Balance as of 
September 
30, 2017

 

Net realized
gain (loss) and
Change in 
Unrealized 
Appreciation 
(Depreciation)

 

Cost of Purchases
and Conversions

 

Proceeds from Sales
and Conversions

 

Net 
Transfers 
in (out 
of) Level 
3

 

Balance as 
of June 30, 
2018

 

Convertible Preferred and Warrants

 

 

 

 

 

 

 

 

 

 

 

 

 

Biotechnology

 

$

4,596,436

 

$

(971,471

)

$

432,693

 

$

(900

)

$

0

 

$

4,056,758

 

Health Care Equipment & Supplies

 

3,782,642

 

6,620,361

 

11,410

 

0

 

0

 

10,414,413

 

Life Sciences Tools & Services

 

3,361,069

 

(1,134

)

1,134

 

0

 

0

 

3,361,069

 

Pharmaceuticals

 

900,000

 

(1,252

)

1,252

 

0

 

0

 

900,000

 

Convertible and Non-Convertible Notes

 

 

 

 

 

 

 

 

 

 

 

 

 

Biotechnology

 

0

 

0

 

349,198

 

0

 

0

 

349,198

 

Health Care Equipment & Supplies

 

154,983

 

141,001

 

477,061

 

0

 

0

 

773,045

 

Common Stocks and Warrants

 

 

 

 

 

 

 

 

 

 

 

 

 

Biotechnology

 

140,479

 

16,338

 

0

 

0

 

0

 

156,817

 

Health Care Equipment & Supplies

 

284,445

 

103,058

 

0

 

0

 

0

 

387,503

 

Health Care Providers & Services

 

322,963

 

68,148

 

0

 

0

 

0

 

391,111

 

Pharmaceuticals

 

138,636

 

37,974

 

0

 

0

 

0

 

176,610

 

Milestone Interests

 

 

 

 

 

 

 

 

 

 

 

 

 

Pharmaceuticals

 

4,660,996

 

4,387,712

 

3,205

 

(3,724,344

)

0

 

5,327,569

 

Other Assets

 

693,984

 

0

 

284,336

 

(716,261

)

0

 

262,059

 

Total

 

$

19,036,633

 

$

10,400,735

 

$

1,560,289

 

$

(4,441,505

)

$

0

 

$

26,556,152

 

 

Net change in unrealized appreciation (depreciation) from investments still held as of June 30, 2018 $10,414,886

 

The following is a quantitative disclosure about significant unobservable inputs used in the determination of the fair value of Level 3 assets.

 

 

 

Fair Value at
June 30, 2018

 

Valuation Technique

 

Unobservable Input

 

Range (Weighted Average)

 

 

 

 

 

 

 

 

 

Private Companies and Other Restricted Securities

 

 

720,787

 

Income approach, Black-Scholes

 

Discount for lack of marketability

 

20%-50% (26.72%)

 

 

7,925,384

 

Probability-weighted expected return model

 

Discount rate
Price to sales multiple

 

18.00%-42.02% (25.95)
2.42x-11.89x (2.40x)

 

 

11,929,242

 

Market approach, recent transaction

 

(a)

 

N/A

 

 

391,111

 

Market Comparable

 

Discount for lack of marketability

 

50%

 

 

 

 

 

 

Price to earnings multiple

 

17.00x

 

 

5,589,628

 

Probability adjusted value

 

Probability of events
Timing of events

 

20%-99% (65.27%)
0.25-18.75(4.15) years

 

 

$

26,556,152

 

 

 

 

 

 

 


(a)         The valuation technique used as a basis to approximate fair value of these investments is based upon subsequent financing rounds. There is no quantitative information as these methods of measure are investment specific.

 



 

TEKLA LIFE SCIENCES INVESTORS

NOTES TO SCHEDULE OF INVESTMENTS

June 30, 2018

(Unaudited, continued)

 

Private Companies and Other Restricted Securities

 

The Fund may invest in private companies and other restricted securities if these securities would currently comprise  40% or less of net assets. The value of these securities represented  6% of the Fund’s net assets at June 30, 2018.

 

At June 30, 2018, the Fund had a commitment of $1,375,416 relating to additional investments in two private companies.

 

The following table details the acquisition date, cost, carrying value per unit, and value of the Fund’s private companies and other restricted securities at June 30, 2018. The Fund on its own does not have the right to demand that such securities be registered.

 

 

 

Acquisition

 

 

 

Carrying Value

 

 

 

Security (#)

 

Date

 

Cost

 

per Unit

 

Value

 

Afferent Milestone Interest

 

7/27/16

 

$

161,872

 

$

331,794.00

 

$

331,794

 

AlterG, Inc.

 

 

 

 

 

 

 

 

 

Series C Cvt. Pfd

 

4/12/13

 

1,429,098

 

0.10

 

233,820

 

Cvt. Promissory Note

 

9/8/17

 

12,336

 

100.00

 

12,336

 

Amphivena Therapeutics, Inc.

 

 

 

 

 

 

 

 

 

Series B Cvt. Pfd

 

7/17/17

 

2,101,222

 

1.50

 

2,100,000

 

Cvt. Promissory Note

 

6/20/18

 

348,265

 

100.00

 

349,198

 

BioClin Therapeutics, Inc.

 

 

 

 

 

 

 

 

 

Series A Cvt. Pfd

 

1/19/16, 10/24/16

 

750,495

 

0.65

 

750,001

 

Series B Cvt. Pfd

 

3/3/17

 

500,000

 

0.75

 

500,000

 

CardioKinetix, Inc.

 

 

 

 

 

 

 

 

 

Series C Cvt. Pfd

 

5/22/08

 

1,653,409

 

0.00

 

0

 

Series D Cvt. Pfd

 

12/10/10

 

546,109

 

0.00

 

0

 

Series E Cvt. Pfd

 

9/14/11

 

1,254,419

 

0.00

 

0

 

Series F Cvt. Pfd

 

12/04/14

 

1,645,812

 

0.00

 

0

 

Cvt. Promissory Note

 

6/20/17

 

51,775

 

0.00

 

0

 

Warrants (expiration 12/11/19)

 

12/10/09, 2/11/10

 

123

 

0.00

 

0

 

Warrants (expiration 6/03/20)

 

6/03/10, 9/01/10

 

123

 

0.00

 

0

 

Warrants (expiration 8/15/24)

 

8/15/14

 

142

 

0.00

 

0

 

Cercacor Laboratories, Inc. Common

 

3/31/98

 

0

 

2.98

 

387,360

 

Ethismos Research, Inc. Milestone Interest

 

10/31/17

 

0

 

0.00

 

0

 

GenomeDx Biosciences, Inc.

 

 

 

 

 

 

 

 

 

Series C Cvt. Pfd

 

2/22/16

 

1,402,469

 

0.33

 

310,800

 

Series D Prime Cvt. Pfd

 

04/04/18

 

48,930

 

0.92

 

146,788

 

Series D Cvt. Pfd

 

04/04/18

 

214,096

 

0.31

 

249,169

 

Warrants (expiration 11/1/27)

 

04/05/18

 

0

 

0.00

 

0

 

IlluminOss Medical, Inc.

 

 

 

 

 

 

 

 

 

Series AA Cvt. Pfd

 

1/21/16

 

960,650

 

1.00

 

951,000

 

Junior Preferred

 

1/21/16

 

1,566,291

 

1.00

 

895,848

 

Cvt. Promissory Note

 

3/28/17

 

286,619

 

100.00

 

285,294

 

Cvt. Promissory Note

 

12/20/17

 

95,243

 

100.00

 

95,083

 

Cvt. Promissory Note

 

01/11/18

 

190,226

 

100.00

 

190,166

 

Cvt. Promissory Note

 

02/06/18

 

190,166

 

100.00

 

190,166

 

Warrants (expiration 1/11/28)

 

01/11/18

 

29

 

0.00

 

0

 

Warrants (expiration 11/20/27)

 

11/21/17

 

87

 

0.00

 

0

 

Warrants (expiration 2/06/28)

 

2/06/18

 

0

 

0.00

 

0

 

Warrants (expiration 3/31/27)

 

3/28/17

 

331

 

0.00

 

0

 

InnovaCare Health, Inc. Common

 

12/21/12

643,527

 

2.64

 

391,111

 

Labcyte, Inc.

 

 

 

 

 

 

 

 

 

Series C Cvt. Pfd

 

7/18/05

 

1,285,854

 

1.26

 

3,081,980

 

Series D Cvt. Pfd

 

12/21/12

 

68,691

 

1.38

 

147,906

 

Series E Cvt. Pfd

 

3/27/17

 

70,826

 

1.61

 

131,183

 

Milestone Pharmaceuticals, Inc.

 

 

 

 

 

 

 

 

 

Series C Cvt. Pfd

 

7/17/17

 

901,252

 

1.37

 

900,000

 

Neurovance Milestone Interest

 

3/20/17

 

3,417,500

 

1,883,922.00

 

1,883,922

 

TargeGen Milestone Interest

 

7/20/10

 

202,855

 

3,111,853.00

 

3,111,853

 

TherOx, Inc. Common

 

9/11/00, 7/8/05

 

2,388,426

 

0.02

 

143

 

Veniti, Inc.

 

 

 

 

 

 

 

 

 

Series A Cvt. Pfd

 

2/28/11

 

2,277,041

 

1.74

 

4,541,534

 

Series B Cvt. Pfd

 

5/24/13

 

1,199,962

 

1.79

 

2,343,362

 

Series C Cvt. Pfd

 

12/12/14

 

821,378

 

2.02

 

1,448,849

 

 

 

 

 

$

28,687,649

 

 

 

$

25,960,666

 

 



 


(#)              See Schedule of Investments and corresponding footnotes for more information on each issuer.

                      Interest received as part of a corporate action for a previously owned security.

 



 

Item 2.  Controls and Procedures.

 

(a.)                              The registrant’s principal executive officer and principal financial officer have concluded, based on their evaluation of the registrant’s disclosure controls and procedures as conducted within 90 days of the filing date of this report, that these disclosure controls and procedures are adequately designed and are operating effectively to ensure that information required to be disclosed by the registrant on Form N-Q is (i) accumulated and communicated to the investment company’s management, including its certifying officers, to allow timely decisions regarding required disclosure; and (ii) recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms.

 

(b.)                              There were no changes in the registrant’s internal control over financial reporting (as defined in Rule 30a-3(d) under the 1940 Act) that occurred during the registrant’s last fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

 

Item 3.  Exhibits.

 

Separate certifications for each principal executive officer and principal financial officer of the registrant as required by Rule 30a-2(a)under the Act (17 CFR 270.30a-2(a)).  Filed herewith.

 



 

SIGNATURES

 

Pursuant to the requirements of the Securities and Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

(Registrant)

Tekla Life Sciences Investors

 

 

 

By (Signature and Title)

/s/ Daniel R. Omstead

 

 

Daniel R. Omstead, President

 

 

 

Date

8/28/18

 

 

Pursuant to the requirements of the Securities and Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

By (Signature and Title)

/s/ Laura Woodward

 

 

Laura Woodward, Treasurer

 

 

 

Date

8/28/18